标题
Recent advances in personalized lung cancer medicine
作者
关键词
-
出版物
Personalized Medicine
Volume 11, Issue 3, Pages 309-321
出版商
Future Medicine Ltd
发表日期
2014-06-17
DOI
10.2217/pme.14.19
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Technical and implementation issues in using next-generation sequencing of cancers in clinical practice
- (2013) D Ulahannan et al. BRITISH JOURNAL OF CANCER
- RETfusion gene: Translation to personalized lung cancer therapy
- (2013) Takashi Kohno et al. CANCER SCIENCE
- Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC
- (2013) Susan Heavey et al. CANCER TREATMENT REVIEWS
- Molecular Pathways: ROS1 Fusion Proteins in Cancer
- (2013) K. D. Davies et al. CLINICAL CANCER RESEARCH
- RET inhibition: implications in cancer therapy
- (2013) Maria Grazia Borrello et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies
- (2013) Tianhong Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
- (2013) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- New Targetable Oncogenes in Non–Small-Cell Lung Cancer
- (2013) Geoffrey R. Oxnard et al. JOURNAL OF CLINICAL ONCOLOGY
- ALKin Lung Cancer: Past, Present, and Future
- (2013) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
- (2013) Neal I. Lindeman et al. Journal of Thoracic Oncology
- Genetic alterations defining NSCLC subtypes and their therapeutic implications
- (2013) Larissa A. Pikor et al. LUNG CANCER
- Tumour heterogeneity in the clinic
- (2013) Philippe L. Bedard et al. NATURE
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
- (2013) Alexander Drilon et al. Cancer Discovery
- Non-small cell lung cancer, locally advanced
- (2012) S. I. Ou et al. ANNALS OF ONCOLOGY
- Histology image analysis for carcinoma detection and grading
- (2012) Lei He et al. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
- (2012) J. De Grève et al. LUNG CANCER
- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
- (2012) Doron Lipson et al. NATURE MEDICINE
- KIF5B-RET fusions in lung adenocarcinoma
- (2012) Takashi Kohno et al. NATURE MEDICINE
- RET, ROS1 and ALK fusions in lung cancer
- (2012) Kengo Takeuchi et al. NATURE MEDICINE
- Current clinical development of PI3K pathway inhibitors in glioblastoma
- (2012) P. Y. Wen et al. NEURO-ONCOLOGY
- Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib
- (2012) B. Sen et al. Science Translational Medicine
- Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
- (2011) C. M. Lovly et al. CANCER RESEARCH
- A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer
- (2011) Zengliu Su et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- (2011) Alice T Shaw et al. LANCET ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study
- (2011) S. Roychowdhury et al. Science Translational Medicine
- Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma
- (2010) Giuseppe Bronte et al. CANCER TREATMENT REVIEWS
- Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2010) Faye M. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- PIK3CA Mutations and Copy Number Gains in Human Lung Cancers
- (2008) H. Yamamoto et al. CANCER RESEARCH
- Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non-Small Cell Lung Cancer
- (2008) Y. L. Choi et al. CANCER RESEARCH
- Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer
- (2008) Amit Kumar et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic mutations affect key pathways in lung adenocarcinoma
- (2008) Li Ding et al. NATURE
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
- A mouse model for EML4-ALK-positive lung cancer
- (2008) M. Soda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now